Pharmacologic activation of GBA1 to reduce alpha-synuclein burden in Parkinson's disease
🧪 Overview
GBA1 mutations represent the strongest genetic risk factor for PD (OR 5-20x), and GCase dysfunction creates a druggable lysosomal impairment that promotes alpha-synuclein aggregation. Multiple chemical scaffolds (ambroxol derivatives, AT337) demonstrate target engagement, and Phase 2 trials show trends toward benefit. The primary translational barrier remains BBB penetration; existing chaperones achieve marginal CNS levels. Enrichment strategies using GBA-PD carriers (15% of PD population) can accelerate trial timelines.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GBA1
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GBA1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |